Assessing the effectiveness of decision AIDS for decision making in prostate cancer testing: A systematic review

Psycho-Oncology

Volumn 24, Issue 10, 2015, Pages 1303-1315

  Ilic, Dragan ^a   Jammal, Walid ^b,c   Chiarelli, Pauline ^d   Gardiner, Robert A ^e,f,g   Hughes, Suzanne ^h   Stefanovic, Dana ⁱ   Chambers, Suzanne K ^f,j,k,l,m  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^h CANCER RESEARCH DIVISION   (Australia)

ⁱ Cancer Council Australia   (Australia)

^j GRIFFITH UNIVERSITY   (Australia)

^k CANCER COUNCIL QUEENSLAND   (Australia)

^l EDITH COWAN UNIVERSITY   (Australia)

^m PROSTATE CANCER FOUNDATION OF AUSTRALIA   (Australia)

more..

Author keywords

decision AIDS; oncology; prostate cancer; PSA testing; systematic review

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCESS TO INFORMATION; ANXIETY; ARTICLE; CANCER SCREENING; CONFLICT; CONFUSION (UNCERTAINTY); DECISION SUPPORT SYSTEM; DISTRESS SYNDROME; EARLY DIAGNOSIS; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; MEDICAL INFORMATION; MULTIMEDIA; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT EDUCATION; PATIENT SATISFACTION; PROSTATE CANCER; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VIDEORECORDING;

EID: 84943820954     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3815     Document Type: Article

References (46)

1. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Center M, Jemal A, Lortet-Tieulent J, et al,. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 2012: 1079-1092.
3. Cuzick J, Thorat M, Andriole G, et al,. Prevention and early detection of prostate cancer. Lancet Oncol 2014; 15: e484-e492.
4. Ilic D, Neuberger M, Djulbegovic M, Dahm P,. Screening for prostate cancer. Cochrane Database Syst Rev 2013; Issue 1:Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub3
5. Thompson I, Ankerst D, Chi C, et al,. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70.
6. Draisma G, Etzioni R, Tsodikov A, et al,. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374-383.
7. Schröder F, Hugosson J, Roobol M, et al,. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
8. Andriole G, Crawford D, Grubb R, et al,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
9. Wolf A, Wender R, Etzioni R, et al,. American Cancer Society guideline for the early detection of prostate cancer (update 2010). CA Cancer J Clin 2010; 60: 70-98.
10. Moyer V, on behalf of the US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134.
11. Royal Australian College of General Practitioners (RACGP). Guidelines for Preventive Activities in General Practice (8th ed.), Royal Australian College of General Practitioners: East Melbourne, 2012.
12. National Collaborating Centre for Cancer. Prostate Cancer: Diagnosis and Treatment. Clinical Guideline, National Institute for Health & Care Excellence (NICE), 2014.
13. Stacey D, Légaré F, Col N, et al,. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014; 1:CD001431. DOI: 10.1002/14651858.CD001431.pub3
14. Stacey D, Bennett C, Barry M, et al,. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011; 10:CD001431. DOI: 10.1002/14651858.CD001431.pub2
15. Albada A, Ausems MG, Bensing JM, van Dulmen S., Tailored information about cancer risk and screening: a systematic review. Patient Educ Couns 2009; 77: 155-171.
16. Higgins J, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org
17. Jadad A, Moore R, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996; 17: 1-12.
18. Schulz K, Chalmers I, Hayes R, Altman D,. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
19. Watts K, Meiser B, Wakefield C, et al,. Online prostate cancer screening decision aid for at-risk men: a randomized trial. Health Psychol 2014; 33: 986-997.
20. Lepore S, Wolf R, Basch C, et al,. Informed decision making about prostate cancer testing in predominantly immigrant Black men: a randomized controlled trial. Ann Behav Med 2012; 44: 320-330.
21. Gattellari M, Ward J,. Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial. J Med Screen 2003; 10: 27-39.
22. Gattellari M, Ward J,. A community-based randomised controlled trial of three different educational resources for men about prostate cancer screening. Patient Educ Couns 2005; 57: 168-182.
23. Taylor K, Williams R, Davis K, et al,. Decision making in prostate cancer screening using decision aids vs usual care: a randomized clinical trial. JAMA Intern Med 2013; 173: 1704-1712.
24. Volk R, Jibaja-Weiss M, Hawley S, et al,. Entertainment education for prostate cancer screening: a randomized trial among primary care patients with low health literacy. Patient Educ Couns 2008; 73: 482-489.
25. Williams RM, Davis KM, Luta G, et al,. Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancer. Patient Educ Couns 2013; 91: 329-336.
26. Evans R, Joseph-Williams N, Edwards A, et al,. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial. J Med Internet Res 2010; 12 (3):e27.
27. Myers R, Daskalakis C, Kunkel E, et al,. Mediated decision support in prostate cancer screening: a randomized controlled trial of decision counseling. Patient Educ Couns 2011; 83: 240-246.
28. Allen J, Othus M, Hart A, et al,. A randomized trial of a computer-tailored decision aid to improve prostate cancer screening decisions: results from the take the wheel trial. Cancer Epidemiol Biomarkers Prev 2010; 19: 2172-2186.
29. Chan E, McFall S, Byrd T, et al,. A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: a cluster RCT. Patient Educ Couns 2011; 84: e44-e51.
30. Partin M, Nelson D, Radosevich D, et al,. Randomized trial examining the effect of two prostate cancer screening educational interventions on patient knowledge, preferences, and behaviors. J Gen Intern Med 2004; 19: 835-842.
31. Sheridan S, Golin C, Bunton A, et al,. Shared decision making for prostate cancer screening: the results of a combined analysis of two practice-based randomized controlled trials. BMC Med Inf Decis Making 2012; 12:130.
32. Volk R, Hawley S, Kneuper S, et al,. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med 2007; 33: 428-434.
33. Kontopantelis E, Springate D, Reeves D,. A re-analysis of the Cochrane library data: the dangers of unobserved heterogeneity in meta-analyses. PLoS One 2013; 8 (7):e69930.
34. Glasziou P, Haynes B,. The paths from research to improved health outcomes. Evidence Based Med 2005; 10: 4-7.
35. Graham I, Logan J, Bennett C, et al,. Physicians' intentions and use of three patient decision aids. BMC Med Inf Decis Making 2007; 7:20.
36. Ilic D, Murphy K, Green S,. What do general practitioners 'think' and 'do' about prostate cancer screening in Australia? Aust Fam Physician 2013; 42: 904-908.
37. Purvis Cooper C, Merritt T, Ross L, John L, Jorgensen C,. To screen or not to screen, when clinical guidelines disagree: primary care physicians' use of the PSA test. Prev Med 2004; 38: 182-191.
38. Young J, Ward J,. Evidence-based medicine in general practice: beliefs and barriers among Australian GPs. J Eval Clin Pract 2001; 7: 201-210.
39. O'Connor A, Wennberg J, Legare F, et al,. Toward the 'tipping point': decision aids and informed patient choice. Health Aff 2007; 26: 716-725.
40. Short D, Frischer M, Bashford J,. Barriers to the adoption of computerised decision support systems in general practice consultations: a qualitative study of GPs' perspectives. Int J Med Inform 2004; 4: 357-362.
41. Silvia K, Ozanne E, Sepucha K,. Implementing breast cancer decision aids in community sites: barriers and resources. Health Expect 2008; 11: 46-53.
42. Brace C, Schmocker S, Huang H, Victor J, McLeod R, Kennedy E,. Physicians' awareness and attitudes toward decision aids for patients with cancer. J Clin Oncol 2010; 28: 2286-2292.
43. Friedberg M, Van Busum K, Wexler R, Bowen M, Schneider E,. A demonstration of shared decision making in primary care highlights barriers to adoption and potential remedies. Health Aff 2013; 32: 268-275.
44. Ilic D, Egberts K, McKenzie J, Risbridger G, Green S,. Informing men about prostate cancer screening; a randomized controlled trial of patient education materials. J Gen Intern Med 2008; 23 (4): 466-471.
45. Schröder F, Hugosson J, Roobol M, et al,. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. The Lancet 2014. DOI: 10.1016/S0140-6736(14)60525-0.
46. Thompson I, Ankerst D, Chi C, et al,. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006; 98: 529-534.